Coronavirus (COVID-19) antibody response in healthcare staff: What proportion of healthcare staff have COVID-19 antibodies? How long do the antibodies last? Do the antibodies protect against recurring infection?

Not Applicable

Completed

• Conditions: COVID-19 (SARS-CoV-2 infection) antibody response in healthcare workers; Respiratory; COVID-19 (SARS-CoV-2 infection)

• Registration Number: ISRCTN15634328
• Lead Sponsor: Abbott (Germany)

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33987193/ 3-month follow-up results (added 28/01/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-13
• Study Completion: 2021-03-31
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1. Aged =18 years
2. Agrees to complete all aspects of the study

Exclusion Criteria

1. Previously participated in this study on a previous occasion
2. Unable or unwilling to provide informed consent
3. Is a vulnerable person as deemed unfit for the study by the Principal Investigator
4. Current symptoms of COVID-19 or has had COVID-19 symptoms within the last 14 days

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of past immune response to the SARS-CoV-2 virus among healthcare workers, as determined using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline

Secondary Outcome Measures

Name	Time	Method
<br> 1. Duration of SARS-CoV-2 antibodies at follow-up visits in those with a positive antibody test result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months<br> 2. Incidence reduction of SARS-CoV-2 infection during the follow-up time period in the population with a positive SARS-CoV-2 antibody result at enrolment in comparison with a population with a negative SARS-CoV-2 antibody result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months<br>